Financial Ratios Legend Biotech Corporation
Equities
LEGN
US52490G1022
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.58 USD | -2.66% |
|
+2.81% | -19.14% |
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
Return on Assets | -28.02 | -25.23 | -23.37 | -17.38 | -10.84 | |||
Return on Total Capital | -169.08 | -52.85 | -29.86 | -21.19 | -12.84 | |||
Return On Equity % | -385.65 | -102.79 | -59.11 | -51.94 | -15.45 | |||
Return on Common Equity | -385.65 | -102.79 | -59.11 | -51.94 | -15.45 | |||
Margin Analysis | ||||||||
Gross Profit Margin % | 100 | 100 | -242.73 | -84.62 | -3.33 | |||
SG&A Margin | 92.34 | 163.25 | 148.75 | 70.47 | 45.32 | |||
EBITDA Margin % | -276.68 | -393.41 | -382.79 | -151.33 | -46.92 | |||
EBITA Margin % | -287.15 | -405.47 | -391.48 | -155.09 | -48.62 | |||
EBIT Margin % | -287.15 | -405.47 | -391.48 | -155.09 | -48.65 | |||
Income From Continuing Operations Margin % | -385.38 | -421.8 | -381.48 | -181.75 | -28.22 | |||
Net Income Margin % | -385.38 | -421.8 | -381.48 | -181.75 | -28.22 | |||
Net Avail. For Common Margin % | -385.38 | -421.8 | -381.48 | -181.75 | -28.22 | |||
Normalized Net Income Margin | -180.71 | -262.96 | -238.16 | -114.1 | -15.32 | |||
Levered Free Cash Flow Margin | -232.23 | -114.51 | -173.2 | -154.73 | -6.15 | |||
Unlevered Free Cash Flow Margin | -232.08 | -113.9 | -167.44 | -149.95 | -4 | |||
Asset Turnover | ||||||||
Asset Turnover | 0.16 | 0.1 | 0.1 | 0.18 | 0.36 | |||
Fixed Assets Turnover | 0.79 | 0.67 | 0.78 | 1.63 | 3.21 | |||
Receivables Turnover (Average Receivables) | 1.44 | 1.43 | 4.6 | 5.6 | 11.47 | |||
Inventory Turnover (Average Inventory) | - | - | 66.27 | 35.35 | 29.91 | |||
Short Term Liquidity | ||||||||
Current Ratio | 3.68 | 3.39 | 3.69 | 6.92 | 4.62 | |||
Quick Ratio | 3.64 | 3.35 | 3.6 | 6.77 | 4.49 | |||
Operating Cash Flow to Current Liabilities | -1.38 | -0.71 | -0.68 | -1.82 | -0.52 | |||
Days Sales Outstanding (Average Receivables) | 253.84 | 254.85 | 79.43 | 65.14 | 31.91 | |||
Days Outstanding Inventory (Average Inventory) | - | - | 5.51 | 10.33 | 12.24 | |||
Average Days Payable Outstanding | - | - | 17.79 | 18.08 | 19.42 | |||
Cash Conversion Cycle (Average Days) | - | - | 67.15 | 57.38 | 24.73 | |||
Long Term Solvency | ||||||||
Total Debt/Equity | 1.32 | 26.1 | 38.23 | 26.26 | 33.69 | |||
Total Debt / Total Capital | 1.3 | 20.7 | 27.66 | 20.8 | 25.2 | |||
LT Debt/Equity | 0.68 | 25.9 | 37.75 | 26.01 | 33.23 | |||
Long-Term Debt / Total Capital | 0.67 | 20.54 | 27.31 | 20.6 | 24.86 | |||
Total Liabilities / Total Assets | 61.13 | 57.87 | 44.08 | 32.31 | 37.7 | |||
EBIT / Interest Expense | -1.16K | -412.52 | -42.43 | -20.29 | -14.12 | |||
EBITDA / Interest Expense | -1.11K | -398.58 | -40.95 | -19.44 | -13.12 | |||
(EBITDA - Capex) / Interest Expense | -1.34K | -447.37 | -42.89 | -20.36 | -13.77 | |||
Total Debt / EBITDA | -0.02 | -0.34 | -0.64 | -0.78 | -1.24 | |||
Net Debt / EBITDA | 2.32 | 2.12 | 1.68 | 2.31 | 2.72 | |||
Total Debt / (EBITDA - Capex) | -0.01 | -0.31 | -0.61 | -0.74 | -1.18 | |||
Net Debt / (EBITDA - Capex) | 1.92 | 1.89 | 1.6 | 2.21 | 2.59 | |||
Growth Over Prior Year | ||||||||
Total Revenues, 1 Yr. Growth % | 33.59 | 16.27 | 70 | 143.7 | 119.97 | |||
Gross Profit, 1 Yr. Growth % | 33.59 | 16.27 | 16.15 | -15.04 | -91.34 | |||
EBITDA, 1 Yr. Growth % | 66.03 | 65.33 | 16.07 | -3.65 | -31.8 | |||
EBITA, 1 Yr. Growth % | 67.21 | 64.18 | 16.25 | -3.46 | -31.03 | |||
EBIT, 1 Yr. Growth % | 67.21 | 64.18 | 16.25 | -3.46 | -31 | |||
Earnings From Cont. Operations, 1 Yr. Growth % | 128.23 | 27.26 | 10.6 | 16.11 | -65.84 | |||
Net Income, 1 Yr. Growth % | 128.23 | 27.26 | 10.6 | 16.11 | -65.84 | |||
Normalized Net Income, 1 Yr. Growth % | 74.01 | 69.24 | 9.75 | 16.76 | -70.48 | |||
Diluted EPS Before Extra, 1 Yr. Growth % | 93.16 | 6.75 | -2.05 | 4.87 | -67.11 | |||
Accounts Receivable, 1 Yr. Growth % | 150 | -32.77 | -99.45 | 36.39K | -93.24 | |||
Inventory, 1 Yr. Growth % | 55.57 | -2.83 | 492 | 87.69 | 23 | |||
Net Property, Plant and Equip., 1 Yr. Growth % | 52.47 | 26.27 | 14.18 | 17.71 | 6.34 | |||
Total Assets, 1 Yr. Growth % | 150.6 | 55.11 | 18.89 | 38.89 | -9.65 | |||
Tangible Book Value, 1 Yr. Growth % | -324.82 | 68.17 | -2.67 | 68.35 | -16.75 | |||
Common Equity, 1 Yr. Growth % | -328.09 | 68.13 | -2.82 | 68.12 | -16.85 | |||
Cash From Operations, 1 Yr. Growth % | 168.47 | -11 | 1.42 | 95.39 | -63.38 | |||
Capital Expenditures, 1 Yr. Growth % | 18.41 | -4.03 | -50.41 | -4.03 | -29.77 | |||
Levered Free Cash Flow, 1 Yr. Growth % | 111.37 | -42.67 | 64.98 | 117.7 | -91.26 | |||
Unlevered Free Cash Flow, 1 Yr. Growth % | 111.57 | -42.94 | 60.22 | 118.25 | -94.14 | |||
Compound Annual Growth Rate Over Two Years | ||||||||
Total Revenues, 2 Yr. CAGR % | 26.14 | 24.49 | 24.9 | 103.54 | 131.53 | |||
Gross Profit, 2 Yr. CAGR % | 26.14 | 24.49 | 34.43 | -0.66 | -72.88 | |||
EBITDA, 2 Yr. CAGR % | 291.34 | 65.68 | 41.52 | 5.75 | -18.72 | |||
EBITA, 2 Yr. CAGR % | 287.34 | 65.69 | 41.16 | 5.94 | -18.18 | |||
EBIT, 2 Yr. CAGR % | 287.34 | 65.69 | 41.16 | 5.94 | -18.38 | |||
Earnings From Cont. Operations, 2 Yr. CAGR % | 944.07 | 70.42 | 29.45 | 13.32 | -37.02 | |||
Net Income, 2 Yr. CAGR % | 944.07 | 70.42 | 29.45 | 13.32 | -37.02 | |||
Normalized Net Income, 2 Yr. CAGR % | 1.06K | 71.59 | 39.75 | 13.2 | -41.32 | |||
Diluted EPS Before Extra, 2 Yr. CAGR % | 860.52 | 43.6 | 11.44 | 1.35 | -41.27 | |||
Accounts Receivable, 2 Yr. CAGR % | 69.1 | 29.65 | -93.94 | 41.72 | 396.57 | |||
Inventory, 2 Yr. CAGR % | 25.93 | 22.95 | 139.84 | 233.33 | 51.94 | |||
Net Property, Plant and Equip., 2 Yr. CAGR % | 94.88 | 38.75 | 19.87 | 15.93 | 11.88 | |||
Total Assets, 2 Yr. CAGR % | 29.63 | 97.16 | 35.76 | 28.5 | 12.02 | |||
Tangible Book Value, 2 Yr. CAGR % | 467.95 | 94.45 | 11.6 | 28 | 18.39 | |||
Common Equity, 2 Yr. CAGR % | 469.24 | 95.83 | 11.59 | 27.82 | 18.24 | |||
Cash From Operations, 2 Yr. CAGR % | -14.87 | 54.57 | -5 | 40.77 | -15.41 | |||
Capital Expenditures, 2 Yr. CAGR % | 47.74 | 6.6 | -10.72 | -31.01 | -17.9 | |||
Levered Free Cash Flow, 2 Yr. CAGR % | -3.5 | 10.08 | 9.19 | 89.52 | -56.37 | |||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -3.55 | 9.87 | 7.4 | 87 | -64.23 | |||
Compound Annual Growth Rate Over Three Years | ||||||||
Total Revenues, 3 Yr. CAGR % | 49.24 | 22.76 | 23.71 | 56.08 | 108.88 | |||
Gross Profit, 3 Yr. CAGR % | 49.24 | 22.76 | 66.26 | 15.36 | -55.96 | |||
EBITDA, 3 Yr. CAGR % | 149.19 | 193.64 | 51.29 | 24.5 | -8.64 | |||
EBITA, 3 Yr. CAGR % | 153.52 | 190.96 | 51.2 | 24.37 | -8.18 | |||
EBIT, 3 Yr. CAGR % | 153.52 | 190.96 | 51.2 | 24.37 | -8.17 | |||
Earnings From Cont. Operations, 3 Yr. CAGR % | 218.82 | 417.67 | 63.79 | 24.84 | -24.02 | |||
Net Income, 3 Yr. CAGR % | 218.82 | 417.67 | 63.79 | 24.84 | -24.02 | |||
Normalized Net Income, 3 Yr. CAGR % | 154.35 | 509.07 | 51.67 | 31.62 | -27.67 | |||
Diluted EPS Before Extra, 3 Yr. CAGR % | 291.51 | 361.81 | 40.13 | 9.2 | -30.35 | |||
Accounts Receivable, 3 Yr. CAGR % | -30.97 | 24.34 | -79 | 10.28 | -48.61 | |||
Inventory, 3 Yr. CAGR % | 446.97 | 15.5 | 107.61 | 121.02 | 139.09 | |||
Net Property, Plant and Equip., 3 Yr. CAGR % | 245.79 | 68.63 | 30.11 | 19.14 | 12.64 | |||
Total Assets, 3 Yr. CAGR % | 44.56 | 37.62 | 65.69 | 36.8 | 14.27 | |||
Tangible Book Value, 3 Yr. CAGR % | 183.58 | 278.55 | 70 | 27.99 | 10.9 | |||
Common Equity, 3 Yr. CAGR % | 184.53 | 279.1 | 70.07 | 27.92 | 10.75 | |||
Cash From Operations, 3 Yr. CAGR % | 354.45 | -13.6 | 34.32 | 20.82 | -10.13 | |||
Capital Expenditures, 3 Yr. CAGR % | 272.93 | 27.95 | -7.88 | -8.54 | -30.6 | |||
Levered Free Cash Flow, 3 Yr. CAGR % | - | -18.88 | 22.08 | 37.43 | -32.03 | |||
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | -19.03 | 20.76 | 36.03 | -41.04 | |||
Compound Annual Growth Rate Over Five Years | ||||||||
Total Revenues, 5 Yr. CAGR % | - | - | 37.63 | 41.94 | 58.96 | |||
Gross Profit, 5 Yr. CAGR % | - | - | 64.34 | 37.28 | -19.51 | |||
EBITDA, 5 Yr. CAGR % | - | - | 99.76 | 97.87 | 17.87 | |||
EBITA, 5 Yr. CAGR % | - | - | 101.24 | 96.56 | 18.14 | |||
EBIT, 5 Yr. CAGR % | - | - | 101.24 | 96.56 | 18.15 | |||
Earnings From Cont. Operations, 5 Yr. CAGR % | - | - | 116.59 | 184.43 | 11.75 | |||
Net Income, 5 Yr. CAGR % | - | - | 116.59 | 184.43 | 11.75 | |||
Normalized Net Income, 5 Yr. CAGR % | - | - | 100.28 | 214.01 | 3.76 | |||
Diluted EPS Before Extra, 5 Yr. CAGR % | - | - | 130.86 | 154 | -1.04 | |||
Accounts Receivable, 5 Yr. CAGR % | - | - | -73.87 | 31.07 | -25.56 | |||
Inventory, 5 Yr. CAGR % | - | - | 293.32 | 76.49 | 83.24 | |||
Net Property, Plant and Equip., 5 Yr. CAGR % | - | - | 122.79 | 42.78 | 22.49 | |||
Total Assets, 5 Yr. CAGR % | - | - | 41.02 | 33.93 | 41.67 | |||
Tangible Book Value, 5 Yr. CAGR % | - | - | 127.48 | 170.58 | 47.09 | |||
Common Equity, 5 Yr. CAGR % | - | - | 127.68 | 170.45 | 47.05 | |||
Cash From Operations, 5 Yr. CAGR % | - | - | 142.99 | 5.03 | 11.64 | |||
Capital Expenditures, 5 Yr. CAGR % | - | - | 88.39 | -0.85 | -12.03 | |||
Levered Free Cash Flow, 5 Yr. CAGR % | - | - | - | 17.57 | -19.11 | |||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | - | - | 16.83 | -25.77 |
- Stock Market
- Equities
- LEGN Stock
- Financials Legend Biotech Corporation
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















